22
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Hematological Remission and Long Term Hematological Control of Acute Myeloblastic Leukemia Induced and Maintained by Granulocyte-colony Stimulating Factor (G-CSF) Therapy

, , , , , & show all
Pages 2137-2142 | Published online: 05 Aug 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (4)

Y. B. Balzhanova & V. G. Savchenko. (2020) The role of interleukin-3 and its receptor in acute leukemia pathogenesis. Russian journal of hematology and transfusiology 65:3, pages 335-350.
Crossref
Thomas Stiehl, Anthony D. Ho & Anna Marciniak-Czochra. (2018) Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis. Scientific Reports 8:1.
Crossref
William K. Decker & Amar Safdar. (2009) Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine & Growth Factor Reviews 20:4, pages 271-281.
Crossref
H W Moon, S Shin, H Y Kim, Y R Kim, H I Cho, S S Yoon, S Park, B K Kim, H Chun, H C Kim, C J Park, Y H Min & D S Lee. (2006) Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia 20:8, pages 1408-1413.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.